Ispronicline
As of the edition of 20 October 2026, Ispronicline is a small molecule: went quiet in 2014; acts on CHRNA4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2014
- Kind
- Small molecule
- Registered trials
- 12, 2 stopped early
- Disease areas
- Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRNA4 | Neuronal acetylcholine receptor subunit alpha-4 | P43681 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 5 | 0 | 2 |
| Phase 2 | 5 | 5 | 0 | 0 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Targacept | Lead sponsor of trials | 2005 to now |
| AstraZeneca | Lead sponsor of trials | 2007 to now |